 However, transdermal selegiline, known by its trade name Emsam, is still contraindicated.Transdermal selegiline results in higher plasma levels at which it behaves like a non-selective MAO inhibitor.Concominant use of entacapone, a component of carbidopa/levodopa/entacapone, with MAO inhibitors may increase toxicity of MAO inhibitors.